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Abstract
Background: The HIV epidemic among former plasma donors (FPDs) in rural Central China in the early-mid 1990s is likely
the largest known HIV-infected cohort in the world related to commercial plasma donation but has never been fully
described. The objectives of this study are to estimate the timing and geographic spread of HIV infection in this cohort and
to demonstrate the impact of antiretroviral therapy on survival outcomes.
Methodology/Principal Findings: HIV-infected FPDs were identified using the national HIV epidemiology and treatment
databases. Locations of subjects were mapped. Dates of infection and survival were estimated using the midpoint date
between initial-final plasma donation dates from 1985–2008 among those with plasma donation windows #2 years. Among
37084 FPDs in the two databases, 36110 were included. 95% were located in focal areas of Henan Province and adjacent
areas of surrounding provinces. Midpoint year between initial-final plasma donation dates was 1994 among FPDs with
known donation dates. Median survival from infection to AIDS was 11.8 years and, among those not treated, 1.6 years from
AIDS to death. Among those on treatment, 71% were still alive after five years. Using Cox proportional hazard modeling,
untreated AIDS patients were 4.9 times (95% confidence interval 4.6–5.2) more likely to die than those on treatment.
Conclusions/Significance: The epidemic of HIV-infected FPD in China was not widespread throughout China but rather was
centered in Henan Province and the adjacent areas of surrounding provinces. Even in these areas, infections were
concentrated in focal locations. Overall, HIV infections in this cohort peaked in 1994, with median survival of 13.4 years from
infection to death among those not treated. Among AIDS patients on treatment, 71% were still alive after five years.
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Introduction
In central China in the early-mid 1990s, plasma donation was
promoted by collectors among poor, rural farmers as an easy
way to supplement meager incomes. Some collectors established
commercial plasma collection stations and, after collecting whole
blood, removed the plasma and returned pooled red blood cells
from blood type-matched donors so that donors could donate
more often without becoming anemic [1,2]. This unsanitary
practice, in contrast to the Ministry of Health issued regulations on
blood-borne pathogen precautions [3], resulted in untold numbers
of human immunodeficiency virus (HIV) and hepatitis C virus
(HCV) infections among the former plasma donors (FPDs)[4–8]
until it was discontinued in 1996 [9]. The extent of the HIV
epidemic among the FPDs was not recognized until they started
developing the acquired immunodeficiency syndrome (AIDS) and
dying in large numbers in the early 2000s. Mass HIV screenings in
known FPD regions were conducted primarily in 2004 and tens of
thousands of infected FPDs were identified [10,11]. In response,
the Chinese government established the National Free Antiretro-
viral Treatment Program (NFATP), initially started among the
FPDs [12,13]. The NFATP has now scaled up nationwide with
analyses demonstrating increasing CD4+ cell counts and reduced
mortality outcomes [14,15].
The HIV-infected FPD cohort in China is unique because it is
likely the largest known HIV-infected cohort in the world related
to commercial plasma donation. Almost all HIV infections
occurred over a relatively short period of time in the early-mid
1990s. The FPDs were primarily poor, rural farmers with almost
no injection drug use or commercial sex work in their communities
and, after at-risk spouses and newborn children were also infected,
new infections were essentially eliminated. Because HIV infections
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around the same times. Small studies of HIV-infected FPDs have
been published but no study has previously examined the entire
cohort or estimated precisely when and where infections occurred
[5–8,16–18]. Identifying when and where infections occurred is
essential to understanding the natural history and geographic
spread of HIV infection in this cohort. In this analysis, we estimate
the time and geographic spread of HIV infection among FPDs in
China and demonstrate the impact of antiretroviral therapy on
survival outcomes.
Methods
Ethics Statement
This analysis was approved by the institutional review board
(IRB) of the National Center for AIDS/STD Control and Pre-
vention (NCAIDS), China CDC. Per the IRB review, individual
informed consent was waived because this analysis used currently
existing data collected during the course of routine treatment and
care and the data were reported in aggregate without the use of
individual identifying information.
HIV infected individuals in this study were identified through
an analysis of two national ongoing, prospective, observational
databases. The first is an epidemiological database of all HIV-
infected patients in China reported to the Chinese Center for
Disease Control and Prevention (China CDC) through the na-
tional surveillance system, initially established in 1997. Former
plasma donors still alive during the mass screenings around 2004
completed a questionnaire about their plasma donating activities
from the early to mid-1990s. Data from FPDs who had already
died were not captured. The second is a treatment database,
previously described [19], of all subjects receiving free national
treatment based on the national HIV treatment criteria (WHO
stage III or IV disease, CD4+ cell count ,200 cells/mL [increased
to ,350/mL in 2008], or total lymphocyte count ,1200/mL) [20].
Antiretroviral treatment scaled up nationwide in 2003 with data
prospectively included in the database since 2004. Information in
the databases include demographics, suspected route of infection,
date and method of HIV diagnosis, date of AIDS diagnosis, CD4+
cell counts pre- and post-treatment initiation, and date of death. In
addition, the epidemiological database also captures self-reported
dates of first and last plasma donations. When only a month was
provided without a specific day, the 1
st of the month was used.
When only a year was provided without a specific month or day,
January 1 was used.
Only individuals infected by plasma donation were eligible for
this analysis. Because the first case of HIV infection in China was
identified in 1985 in a foreigner [21], FPD subjects were not
thought to be infected with HIV in China before 1985. Plasma
donations recorded before 1985 were not felt to be the source of
HIV infection and subjects with this history were excluded.
Subjects with other HIV risk factors and those missing key dates
needed to calculate infection times and survival were also
excluded. Those initiating treatment had 16 different signs or
symptoms collected at baseline (yes/no). We included five that
more typically represent immunosuppression (fever, diarrhea,
dyspnea, oral candidiasis, and oral hairy leukoplakia) in the
mortality risk factor analysis and did not include the less specific
signs/symptoms, such as cough, headache, or visual changes. The
most commonly used treatment regimens were nevirapine with
zidovudine or stavudine and didanosine or lamivudine.
The date of HIV infection was estimated as the midpoint
between the initial and final plasma donation dates. Only subjects
with an initial-to-final plasma donation date range of #2 years
were used to estimate infection times, due to concerns that
intervals longer than two years may substantially bias survival
estimates [22]. The baseline characteristics of these subjects were
compared against subjects with initial-to-final dates longer than
two years or with missing dates using the chi-squared test to
determine if there were significant differences between these two
groups. The geographic distributions of HIV-infected FPDs were
plotted on a map (MapInfo Professional, version 6.5; Pitney Bowes
Software Inc., Troy, New York) using county level data, with the
midpoint of the #2 year cohort used to estimate the timing of HIV
spread across different counties. Kaplan-Meier survival curves
were used to estimate time from HIV infection to AIDS diagnosis
(earliestdate of AIDS-defining illness orCD4+ cellcount ,200/mL)
andfrom AIDS diagnosistodeath forthe #2 year cohort.Surviving
patients were censored on their date of last contact recorded in the
databases or on 30-Aug-2008 and the log-rank test was used to
compare survival curves. Cox proportional hazard modeling was
used to assess risk factors for disease progression, from infection to
AIDS and from AIDS to death. Covariates pre-determined to be
clinically relevant were entered into multivariable models. Data
were analyzed using SPSS version 17.0 (SPSS Inc., Chicago,
Illinois) and SAS version 9.13 (SAS Institute Inc., Cary, NC). All
hypothesis testing was two-sided with alpha=0.05.
Results
Between the two national databases, 37084 individuals were
identified as being HIV-infected by plasma donation, with 36110
subjects included in the overall analysis (Figure 1). These FPDs were
predominantly male (58%), married (81%), educated to primary
school (63%), and farmers (95%, Table 1). Median age (calculated)
at infection was 29 years (interquartile range, 24–36). Almost 80%
were from Henan Province. Initial and final plasma donation dates
wererecordedfor25960(72%),withJanuaryrecordedasthemonth
in 48% and the first of the month as the date in 97%. Among those
withrecorded dates, 16038 (62%) donated plasmawithin a two year
window and 9922 (38%) donated plasma for longer than 2 years.
When baseline demographics of those donating within a two year
period were compared to the remaining FPDs (.2 years and
missing dates), all characteristics were statistically significantly
different from each other due to the large sample size (Table 1).
These differences, however, were not clinically meaningful except
that slightly more of those donating within a two year period were
from Henan Province. About 95% of all FPDs were concentrated in
focal areas of Henan and the adjacent areas of surrounding
provinces (Table 1, Figure 2a, 2b).
Among the 25960 with known plasma donation dates, the peak
midpoint yearbetween initialand final donationswas1994 (Figure 3).
There was a relatively gradual rise in initial donations before 1993,
followed by a sharp drop in final plasma donations in 1996, when
commercial plasma donation became illegal [9]. The vast majority
were confirmed HIV positive by Western blot in 2004 due to mass
screenings [10,11], with HAART begun shortly thereafter for those
still alive who met treatment eligibility criteria. Among the 16038
who donated plasma within a two year window, the estimated peak
year of infection overall was also 1994 (32.3%, Table 1). When
stratified by counties, however, HIV infections did not occur
simultaneously across the provinces. In some counties in Henan
and Northern Anhui, infections peaked as early as 1992 (Figure 2c).
Among those with a plasma donation window of #2 years, an
additional 1008 FPDs were excluded with missing or unconfirmed
dates for the survival analysis (Figure 1). Among the remaining
15030 subjects, there was a median 11.8 years from HIV infection
to AIDS, with no difference noted between those with a plasma
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Among those not receiving HAART, 45% died after 1 year with a
median 1.6 years from AIDS to death, for a mortality rate of 34.3/
100 person-years (Figure 4b). In contrast, mortality among those
receiving HAART at one year was only 7% with 71% still
surviving at five years (overall mortality rate 6.7/100 person-
years). Risk factors associated with HIV disease progression from
infection to AIDS and from AIDS to death were examined (Table
S1). From HIV infection to AIDS, only three factors could be
analyzed because the data used (gender and ethnicity) were
collected at the time of HIV diagnosis. The age at infection was
estimated as described above. In the adjusted analysis, both gender
and ethnicity were of borderline significance while increasing age
at time of infection was associated with a significantly greater risk
of disease progression. Compared to ,18 year olds, 18–44 year
olds were 1.3 fold (95% confidence interval [CI] 1.2–1.5) more
likely to develop AIDS and $45 years olds were 1.6 fold (95% CI
1.4–1.8) more likely. In the overall adjusted analysis from AIDS to
death, treatment with HAART was by far the most important risk
factor, with those not receiving HAART being 4.9 fold (95% CI
4.6–5.2) more likely to die. Among AIDS patients who received
HAART, factors significantly associated with death included
baseline CD4+ cell count ,50/mL (adjusted hazard ratio [AHR]
3.1, 95% CI 2.1–4.7), age $60 years (AHR 2.8, 95% CI 1.4–5.6),
baseline hemoglobin ,8 g/dL (AHR 2.4, 95% CI 1.6–3.5),
having 4–5 baseline signs or symptoms (AHR 1.7, 95% CI 1.2–
2.5), and being male (AHR 1.4, 95% CI 1.1–1.7).
Discussion
The specific circumstances surrounding when and where the
unique cohort of FPDs in China became infected with HIV have
never before been fully analyzed. This analysis shows that about
95% of HIV-infected FPDs were located in focal areas of Henan
and adjacent areas of surrounding provinces. Using a subset of
HIV-infected FPDs with known plasma donation dates within a
two year window to represent the entire cohort, we estimated that
the overall peak year of HIV infections was 1994 (Table 1) but as
early as 1992 in some counties in Henan and Northern Anhui
(Figure 2c). The median time from HIV infection to AIDS was
11.8 years and, among those not on HAART, from AIDS to death
was 1.6 years (Figure 4). The major risk factor for development of
AIDS was being older at time of HIV infection and for death was
not receiving HAART (Table S1). Among those who received
HAART, additional risk factors for death included baseline CD4
cell count ,50/mL, age $60 years at AIDS diagnosis, baseline
hemoglobin ,8 g/dL, and having 4–5 baseline signs and
symptoms at treatment initiation.
The concentration of this HIV epidemic in Henan Province is
striking and the reasons for why this occurred are complex. The
primary source of plasma used by industry is from developing
countries and plasma donors in poor countries are less likely to be
injection drug users (IDUs) [23]. Thus, it was felt that these mostly
rural and poor populations, such as in Henan Province, were
‘‘safer,’’ without many risk factors for blood-transmitted infections
such as HBV, much less HIV. In the early 1990s, Henan
permitted paid plasma donation at commercial plasma collection
stations, which was seen in rural areas as a relatively easy means of
income supplementation. Donating plasma quickly became
popular as people felt it was less harmful than donating whole
blood since they received red blood cells back and could replace
plasma easily by drinking more fluids. Once the government
realized that HIV had entered the plasma pool, they acted quickly
to shut down the collection stations. By that time, however, tens of
Figure 1. Selection criteria for HIV-infected former plasma donors (FPD) included in the analysis. Selection criteria for the 36110 HIV-
infected former plasma donors (FPD) included in the overall analysis, the 16038 FPDs included in the estimation of the date of HIV infection, and the
15030 FPDs included in the survival analysis.
doi:10.1371/journal.pone.0013737.g001
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not caused by injection drug use as demonstrated by distinct
molecular epidemiology patterns among FPDs and IDUs in China
[24]. Previous studies focused on determining HIV prevalence and
risk factors among FPD communities and found prevalences
ranging from 7.2–25.9% among those who previously donated
plasma [7,8,16,17]. Hepatitis B virus (HBV) infections were
uncommon in FPDs because those infected were screened out
before donating. Hepatitis C virus infection testing was not yet
available at that time and thus co-infection rates with HIV have
Table 1. Characteristics of the 36110 former plasma donors included in the analysis from 1985–2008, stratified by plasma donation
window #2 years vs. .2 years.
Characteristic Total Interval between dates of first and last plasma donation P-value
0–2 years .2 years or missing dates{
No. (%) No. (%) No. (%)
Overall 36110 16038 20072
Gender
Male 20875 (57.8) 9137 (57.0) 11738 (58.5) ,0.001
Female 15235 (42.2) 6901 (43.0) 8334 (41.5)
Estimated age at HIV infection (years)
,18 — 765 (4.8) — —
18–44 — 14349 (90.4) —
$45 — 767 (4.8) —
Missing 157
Ethnicity
Han 35243 (97.6) 15831 (98.7) 19412 (96.7) ,0.001
Other 867 (2.4) 207 (1.3) 660 (3.3)
Marriage*
Married/Live Together 28921 (81.2) 12868 (80.3) 16053 (82.0) ,0.001
Single/Divorced/Widowed 6680 (18.8) 3147 (19.7) 3533 (18.0)
Missing 509 23 486
Education*
Primary school & below 22021 (63.0) 10138 (63.7) 11883 (62.5) 0.013
Middle school & above 12908 (37.0) 5765 (36.3) 7143 (37.5)
Missing 1181 135 1046
Occupation*
Farmer 34163 (94.6) 15511 (96.7) 18652 (92.9) ,0.001
Others 1947 (5.4) 527 (3.3) 1420 (7.1)
Province*
Henan 28644 (79.3) 13489 (84.1) 15155 (75.5) ,0.001
Anhui 3189 (8.8) 1360 (8.5) 1829 (9.1)
Hubei 1523 (4.2) 650 (4.1) 873 (4.3)
Shanxi 724 (2.0) 206 (1.3) 518 (2.6)
Shandong 198 (0.5) 91 (0.6) 107 (0.5)
Other 1832 (5.1) 242 (1.5) 1590 (7.9)
Estimated year of HIV infection
#1990 — 554 (3.5) — —
1991 — 1032 (6.4) —
1992 — 2649 (16.5) —
1993 — 3669 (22.9) —
1994 — 5174 (32.3) —
1995 — 2469 (15.4) —
1996 — 313 (2.0) —
$1997 — 178 (1.1) —
{N=9922 for those with interval .2 years and N=10150 for those with missing dates.
*Data as of when the person was identified as HIV positive.
doi:10.1371/journal.pone.0013737.t001
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infected FPDs were not homogenously distributed across Henan
but were located in focal areas (Figure 2c). It is likely that, if we
were able to use village (instead of county) level data, the focal
areas would be even more distinctly defined. These focal areas are
hypothesized to be where previous commercial plasma collection
stations were located. The majority of infections were in central
Henan, near the border with Anhui, and HIV appears to have
Figure 3. Distribution of the estimated time of HIV infection. Distribution of the estimated time of HIV infection among the subset of former
plasma donors (FPD; N=25960) with known initial and final plasma donation dates, using the midpoint of the donation window as the date of
infection and stratified by the duration of the plasma donation window, from those who only donated once (first and last donation dates the same)
to those who donated for more than three years. Dates of Western blot (WB) confirmation of HIV infection and initiating highly active antiretroviral
therapy (HAART) are also shown.
doi:10.1371/journal.pone.0013737.g003
Figure 2. Distribution of HIV infection by region among former plasma donors (FPD) included in the analysis. Figure 2a: Map of the
People’s Republic of China showing the geographic distribution of all 36110 HIV-infected FPDs included in this analysis by location. Each dot
represents 20 people. Figure 2b: Close-up map of Henan Province and the surrounding province showing the geographic distribution of all HIV-
infected FPDs included in this analysis from this region. Each dot represents 20 people. Figure 2c: Close-up map of Henan Province and the
surrounding province showing the geographic distribution of only the 16038 HIV-infected FPDs included in this analysis from this region with a #2
year plasma donation window. Estimated median peak year of HIV infection is indicated by county. Each dot represents 20 people.
doi:10.1371/journal.pone.0013737.g002
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1992. Infections peaked in the surrounding counties in subsequent
years, suggesting that commercial plasma collection stations
branched out to those areas. Alternatively, it is possible that
commercial plasma collection stations were already widespread
but that HIV first entered the ones that adhered the least to blood-
borne pathogen precautions
A number of studies have analyzed the natural history of HIV
infection and estimated the time from seroconversion to death,
ranging from 7.5–12.6 years in different populations [27–33].
Among our FPDs, median time from seroconversion to death was
slightly longer at 13.1 years, due to the survival bias in our cohort.
Mass HIV screening surveys were done in 2004–2005 [10,11],
when most of the baseline demographics data in the databases
were collected. This was likely at least ten years after HIV
infection occurred for most. Missing from the screening surveys,
therefore, were those who had already developed AIDS and died,
with shorter times to death, or those with typical times to death but
were infected earlier. The bias from shorter times to death may be
large because many people donated repeatedly and higher HIV
inoculum received has been correlated with faster progression to
AIDS [34]. Thus the true median time from infection to death is
shorter than our estimate of 13.4 years. The bias from those
infected earlier affects our estimate of the date of HIV infection, as
those infected earlier (and therefore died earlier) were not
included. Thus, the true peak time of infection is possibly before
1994. Due to insufficient HIV infection and mortality data from
the 1990s to the early 2000s, the extent of these survival biases on
our results is uncertain.
The impact of HAART in significantly reducing mortality
among AIDS patients in this study (Figure 4) validates our
previous analysis of decreased mortality among a subset of 4093
FPD AIDS patients [14]. In that study, we demonstrated that
mortality declined from 30.2/100 person-years pre-treatment to
4.6/100 person-years post-treatment. Our current results are also
consistent with our analysis of the five year outcomes of the
NFATP, which included 48,785 patients with FPDs comprising
over 50% [15]. We demonstrated that mortality among treated
AIDS patients dropped from 22.6/100 person-years at treatment
initiation to 4–5/100 person-years across five years of treatment.
The results of this study, with a Kaplan-Meier analysis showing
continued survival of 71% of treated FPD AIDS patients at five
years, further confirms the positive effect of the NFATP in
reducing long-term mortality.
There are a few limitations associated with this analysis, in
addition to the survival bias discussed above. First, because
baseline demographics data, including initial and final plasma
donation dates, were collected primarily in 2004–2005, there may
be misclassification of donation durations regarding the plasma
donation dates (within two years versus greater than two years or
unknown), which occurred roughly 10 years earlier. However, this
misclassification error is felt to have a random effect, not
systematically altering the donation dates to be earlier or later.
Furthermore, our estimate of 13.4 years survival from infection to
death is consistent with previous natural history estimates,
accounting for the survival bias in our cohort. Second, we only
use the 44% of FPDs with up to a two year donation window to
represent all FPDs when estimating time of infection and survival.
However, the use of a two year window has been validated by
other studies [22]. Furthermore, there were no clinically significant
differences between the baseline demographics and regional
distribution (Table 1) or temporal distribution (Figure 3) between
our cohort and those with larger or unknown donation windows.
Third, with so many infections concentrated over a relatively short
period of time (few years), the concentration of HIV in the pooled
plasma of donors may have been quite high, especially during the
peak infection years. Infections may have occurred early during
the plasma donation period rather than at the midpoint. However,
Figure 4. Survival from HIV infection to AIDS and from AIDS to death. Kaplan-Meier plots showing survival from HIV infection to AIDS in
former plasma donors with plasma donation window #2 years (Figure 4a, N=15030) and from AIDS to death among the same cohort who were
diagnosed with AIDS (N=12242), stratified by whether or not on highly active antiretroviral therapy (HAART; Figure 4b).
doi:10.1371/journal.pone.0013737.g004
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results (Figure 4a). Finally, there is likely bias due to residual
confounding. Several potentially confounding factors could not be
included in the Cox proportional hazards regression analysis of
HIV disease progression (Table S1) because the data were
collected at the time of HIV diagnosis, roughly ten years after
HIV infection first occurred. Only gender, age (calculated), and
race/ethnicity would have been unchanged at the time of infection
and therefore could be included in the analysis. Other relevant
factors or potential confounders, such as details related to the
plasma donation events, were not known.
In conclusion, this analysis demonstrates the devastating impact
that not adhering strictly to blood-borne pathogen precautions can
have, infecting tens of thousands of people with HIV across central
China. Infections peaked in 1994, with 95% of HIV-infected FPDs
concentrated in focal areas of Henan and the adjacent areas of
surrounding provinces. These results are generalizable to all FPDs
in China, given the above limitations, and have implications for
those still alive. Studies have shown high rates of HCV co-
infection in this population [5,6], and HCV was likely acquired at
or around the time of HIV infection. With the date of HIV
infection now estimated, the natural history of HCV infection can
be studied and strategies to deal with chronic HCV infection can
be examined. Future large-scale blood product practices in
resource-limited settings must be certain to adhere strictly to
international blood-borne pathogen precautions to prevent repeat
occurrences of such a public health disaster.
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